Collegium Pharmaceutical (NASDAQ:COLL) Rating Increased to Buy at Needham & Company LLC

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) was upgraded by equities researchers at Needham & Company LLC from a "hold" rating to a "buy" rating in a research report issued to clients and investors on Friday, MarketBeat Ratings reports. The firm currently has a $46.00 price target on the specialty pharmaceutical company's stock. Needham & Company LLC's price target points to a potential upside of 39.78% from the company's previous close.

Several other research analysts have also recently commented on COLL. Piper Sandler reiterated a "neutral" rating and set a $37.00 price target on shares of Collegium Pharmaceutical in a report on Friday, October 11th. StockNews.com lowered Collegium Pharmaceutical from a "strong-buy" rating to a "buy" rating in a report on Wednesday, October 23rd. One analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $43.80.

Collegium Pharmaceutical Stock Down 1.3 %

Shares of COLL traded down $0.43 during midday trading on Friday, hitting $32.91. The company had a trading volume of 686,743 shares, compared to its average volume of 622,707. The company's 50-day simple moving average is $30.57 and its 200-day simple moving average is $34.04. The company has a debt-to-equity ratio of 3.43, a quick ratio of 0.88 and a current ratio of 0.97. Collegium Pharmaceutical has a 1 year low of $28.39 and a 1 year high of $42.29. The firm has a market capitalization of $1.06 billion, a P/E ratio of 14.19 and a beta of 0.82.

Institutional Trading of Collegium Pharmaceutical

Institutional investors and hedge funds have recently bought and sold shares of the business. GAMMA Investing LLC lifted its position in Collegium Pharmaceutical by 124.5% during the 3rd quarter. GAMMA Investing LLC now owns 1,428 shares of the specialty pharmaceutical company's stock worth $55,000 after acquiring an additional 792 shares during the period. CWM LLC increased its holdings in shares of Collegium Pharmaceutical by 97.5% in the 3rd quarter. CWM LLC now owns 1,491 shares of the specialty pharmaceutical company's stock valued at $58,000 after purchasing an additional 736 shares in the last quarter. TD Private Client Wealth LLC lifted its stake in shares of Collegium Pharmaceutical by 39.5% in the third quarter. TD Private Client Wealth LLC now owns 1,707 shares of the specialty pharmaceutical company's stock valued at $66,000 after purchasing an additional 483 shares during the period. Virtus Fund Advisers LLC purchased a new stake in Collegium Pharmaceutical during the third quarter worth about $72,000. Finally, China Universal Asset Management Co. Ltd. grew its position in Collegium Pharmaceutical by 61.2% during the third quarter. China Universal Asset Management Co. Ltd. now owns 6,196 shares of the specialty pharmaceutical company's stock worth $239,000 after buying an additional 2,352 shares during the period.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.